相关实验视频

Updated: Jun 25, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

肌肉侵入性和转移性膀癌的外科免疫检查点封锁

Chethan Ramamurthy¹, Karen M Wheeler¹, Shaun Trecarten¹

¹Department of Urology, University of Texas Health San Antonio (UTHSA), San Antonio, TX 78229, USA.

Journal of cancer immunology

|May 24, 2024

概括

新辅助免疫疗法与化疗相结合,显示出对肌肉侵入性膀癌的潜在安全性. 在转移性膀癌模型中,外科免疫疗法改善了生存率,尽管时间并没有显著改变结果.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
癌症研究癌症研究

背景情况:

检查点抑制剂对膀癌有希望,但最佳时间 (新辅助剂与辅助剂) 尚不清楚.
结合免疫疗法和化疗正在研究肌肉侵入性和转移性膀癌.

研究的目的:

为了评估新辅助抗PD-1和抗CTLA-4与肌肉侵入性膀癌的西斯丁-凝胺化疗的疗效和安全性.
为了在转移性膀癌的小鼠模型中比较新辅助剂与辅助剂的抗PD-L1疗效.

主要方法:

在肌肉侵入性膀癌患者中,新辅助免疫疗法加化疗的II期试验.
自发转移性膀癌的小鼠模型来评估新辅助与辅助抗PD-L1疗法.

主要成果:

临床试验被提前停止;在4名患者中,有50%的病理反应完全发生,并有可管理的不良事件.
治疗反应与尿液中CD8+和IFNγ+CD4+T细胞的增加相关.
在小鼠模型中,新辅助剂和辅助剂抗PD-L1与单独免疫疗法相比,改善了生存率,时间策略之间没有显著差异.

结论:

新辅助化疗和免疫疗法组合似乎对肌肉侵入性膀癌是安全的.
周围手术免疫疗法显示出局部晚期和转移性膀癌的潜力.
需要进一步的随机试验来确认免疫治疗在新辅助剂环境中的疗效.

关键词:

膀癌是一种癌症.免疫检查点抑制剂免疫检查点抑制剂免疫治疗是一种免疫疗法.在T细胞,T细胞.αPD-L1疗法治疗的方法

更多相关视频

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Minimally Invasive Establishment of Murine Orthotopic Bladder Xenografts

Published on: February 11, 2014

Mouse Bladder Wall Injection

Mouse Bladder Wall Injection

Published on: July 12, 2011

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.